Tonix’s TNX-102 SL: A Fibromyalgia Breakthrough
Tonix advances TNX-102 SL for fibromyalgia, a non-opioid therapy improving sleep and chronic pain symptoms.
Tonix Pharmaceuticals is pioneering a potential breakthrough in fibromyalgia treatment with TNX-102 SL, a sublingual formulation of cyclobenzaprine. Fibromyalgia, which affects 10 million Americans, often leads patients to opioids due to limited treatment options, but TNX-102 SL offers a non-opioid alternative.
The drug, which received FDA Fast Track designation, targets poor sleep quality—a key factor in fibromyalgia’s chronic pain. Phase 3 trials showed significant improvements in pain, sleep, and overall symptoms. If FDA approves the drug, it could be available as early as 2025, potentially transforming first-line therapy for fibromyalgia.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion